GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » InnoCare Pharma Ltd (FRA:33C) » Definitions » Total Current Assets

InnoCare Pharma (FRA:33C) Total Current Assets : €1,125.71 Mil (As of Dec. 2023)


View and export this data going back to 2021. Start your Free Trial

What is InnoCare Pharma Total Current Assets?

Total current assets includes Cash, Cash Equivalents, Marketable Securities, Total Receivables, Total Inventories, and Other Current Assets. InnoCare Pharma's total current assets for the quarter that ended in Dec. 2023 was €1,125.71 Mil.

InnoCare Pharma Total Current Assets Historical Data

The historical data trend for InnoCare Pharma's Total Current Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

InnoCare Pharma Total Current Assets Chart

InnoCare Pharma Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Total Current Assets
Get a 7-Day Free Trial 309.09 514.40 891.64 1,259.22 1,125.71

InnoCare Pharma Quarterly Data
Dec17 Sep18 Dec18 Jun19 Sep19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Sep22 Dec22 Jun23 Sep23 Dec23 Mar24
Total Current Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1,259.22 1,174.33 1,148.54 1,125.71 -

InnoCare Pharma Total Current Assets Calculation

Total Current Assets are the asset that can be converted to cash or used to pay current liabilities within 12 months.

InnoCare Pharma's Total Current Assets for the fiscal year that ended in Dec. 2023 is calculated as

Total Current Assets=Cash, Cash Equivalents, Marketable Securities+Total Receivables+Total Inventories+Other Current Assets
=1056.267+47.801+15.295+6.348
=1,125.71

InnoCare Pharma's Total Current Assets for the quarter that ended in Dec. 2023 is calculated as

Total Current Assets=Cash, Cash Equivalents, Marketable Securities+Total Receivables+Total Inventories+Other Current Assets
=1056.267+47.801+15.295+6.348
=1,125.71

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Total Current Assets is linked to the Current Ratio, which is the result of dividing total current assets by total current liabilities. It is frequently used as an indicator of a company's liquidity, its ability to meet short-term obligations.

Total Current Assets is also linked to Working Capital, Net working capital is calculated as Total Current Assets minus Total Current Liabilities.

InnoCare Pharma  (FRA:33C) Total Current Assets Explanation

In Ben Graham's calculation of liquidation value, inventory is only considered worth half of its book value, and accounts receivable is considered worth 75% of its value. Therefore the liquidation value is lower than calculated from total current assets.

InnoCare Pharma's Liquidation Value for the quarter that ended in Dec. 2023 is

Liquidation value
= Cash, Cash Equivalents, Marketable Securities-Total Liabilities+(0.75 * Accounts Receivable)+(0.5 * Total Inventories)
=1056.267-351.69+0.75 * 35.546+0.5 * 15.295
=738.88

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

InnoCare Pharma Total Current Assets Related Terms

Thank you for viewing the detailed overview of InnoCare Pharma's Total Current Assets provided by GuruFocus.com. Please click on the following links to see related term pages.

InnoCare Pharma (FRA:33C) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » InnoCare Pharma Ltd (FRA:33C) » Definitions » Total Current Assets
Comparable Companies
HKSE:01541 HKSE:09966 HKSE:06660 HKSE:01952 HKSE:02162 HKSE:06826 HKSE:02315 HKSE:01530 HKSE:06955 HKSE:02105 OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA HKSE:02269 XBRU:ARGX BNTX
Traded in Other Exchanges
09969:Hong Kong 33C:Germany 688428:China
Address
No. 8 Life Science Park Road, Building 8, Zhongguancun Life Science Park, Changping District, Beijing, CHN, 102206
Website
https://www.innocarepharma.com
InnoCare Pharma Ltd is a commercial-stage biopharmaceutical company. It discovers, develops, and commercializes drugs for the treatment of cancer and autoimmune diseases. The company's main product pipeline includes orelabrutinib, ibrutinib, zanubrutinib, tafasitamab, ICP-490, ICP-B02, ICP-248, ICP-192, ICP-723, and ICP-189, among others. Its products are mainly used to treat hematological tumors, solid tumors, and autoimmune diseases. The company is also developing products for the treatment of autoimmune diseases caused by abnormal B-cell or T-cell function.

InnoCare Pharma (FRA:33C) Headlines

No Headlines